TUM – Technical University of Munich Menu
Eine therapeutische Imfpung gegen Hepatitis B könnte weltweit Millionen Menschen helfen. (Bild: tommyS / pixelio.de)
Eine therapeutische Imfpung gegen Hepatitis B könnte weltweit Millionen Menschen helfen. (Bild: tommyS / pixelio.de)
  • Research news

Hepatitis B: Therapeutic vaccine to soon undergo clinical studies

Treatment for chronic viral infections

Around 260 million people worldwide suffer from chronic Hepatitis B, which is currently incurable. A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München has developed a therapeutic vaccine at the German Center for Infection Research that will shortly undergo testing in initial clinical studies. The project has received 2.6 million euros from the new proof-of-concept initiative launched by Helmholtz, Fraunhofer and Hochschulmedizin (the German University Hospitals Association) and was singled out from 83 applications.

“We have developed a therapeutic vaccine that may offer the prospect of a cure for the first time using two consecutively administered vaccines,” explains Ulrike Protzer, Professor of Virology at the TUM and Research Group Leader at the Helmholtz Zentrum in Munich.


Anyone not yet infected with the Hepatitis B virus can receive the vaccine. It cannot, however, be used to treat individuals who already have a chronic infection; the available drugs may stem the proliferation of viruses in the body but cannot cure the disease. Patients with chronic Hepatitis B therefore have a higher risk of suffering from liver cirrhosis or liver cancer.

Dual impact against Hepatitis B

Two different components are combined in the new therapeutic vaccine. Proteins of the Hepatitis B virus are administered directly in an initial vaccine (prime) to trigger the formation of suitable antibodies and to prepare immune cells, so-called T cells, for their deployment. The antibodies neutralize the virus and prevent it from spreading further. The T cells are important immune cells in the human body that can destroy cells infected with viruses.


This immune response is then boosted with a second vaccine. To this effect, the researchers use a harmless smallpox vaccination virus that carries parts of the genotype of the Hepatitis B virus within it. This viral vector is trimmed to activate T cells and aims to increase the number of specific T cells combatting the Hepatitis B virus and to make them target the infected cells.


This ‘prime boost vaccine’ proved extremely successful in studies using animal models. “Both effective antibodies, which reduced the quantity and spread of the virus in the blood, and T cells, which killed the infected liver cells, were formed,” explains Protzer.

Preparation under way for first clinical study

The researchers are now using the successfully secured funding to prepare the first clinical study on humans. This involves both the specialist production of the vaccine components as well as the toxicological and pharmacodynamics studies beforehand. The clinical study is being carried out by Prof. Dr. Marylyn Addo at the University Hospital of Hamburg-Eppendorf (UKE).

Project selected from 83 applications

The proof of concept is a key stage in securing authorization for drugs and vaccines. To facilitate this step, which often presents researchers with an insurmountable obstacle, the Fraunhofer-Gesellschaft and the Helmholtz Society together with the Deutsche Hochschulmedizin launched the PoC initiative. From 83 applications, the project was one of four selected to receive funding.

 

More information:


The project is being carried out in cooperation with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig and the University Hospitals “Rechts der Isar” in Munich and Hamburg-Eppendorf. The German Center for Infection Research (DZIF) is also providing funding of 1.3 million euros for the project.

ContaCt:

Prof. Ulrike Protzer
Institute of Virology
Technical University of Munich
Tel: +49 89-4140 6821
E-Mail: protzer(at)tum.de

Corporate Communications Center

Technical University of Munich Dr. Vera Siegler
vera.siegler(at)tum.de

Article at tum.de

The image shows in a HBV-specific T cell (green) attacking a target cell, in which viral proteins are produced (red) and HBV negative cells (blue).

Checkmate for hepatitis B viruses in the liver

Researchers from Munich, Hamburg and Heidelberg have for the first time succeeded in conquering a chronic infection with the hepatitis B virus (HBV) in a mouse model. The team showed in its publication, that T-cell therapy...

Percy Knolle, Professor für Molekulare Immunologie an der TUM, untersucht die Ursachen des Leberversagens. (Bild: A. Heddergott / TUM)

Liver failure caused by attack on blood vessel cells

In severe cases, a viral hepatitis infection can result in liver failure. A team from the Technical University of Munich (TUM) has now discovered how this occurs: by immune cells attacking cells in the vascular system,...

Das wissenschaftliche Team der Zika-Virus Studie (von links nach rechts): Pietro Scaturro, Prof. Andreas Pichlmair und Dr. Alexey Stukalov. (Bild: A. Eckert / TUM)

Zika virus proteins inhibit brain development

In healthy individuals, the Zika virus causes flu-like symptoms. If a pregnant woman becomes infected, the unborn child can suffer from severe brain abnormalities as a result of mechanisms that have not yet been explained....

Akram Abdellatif, Prof. Ulrike Protzer und Hanaa Gaber (von links nach rechts) haben gemeinsam die ISS Research Competition gewonnen. (Bild: M. Stobrawe / MRI)

Hepatitis C virus proteins in space

Two Egyptian researchers at Technische Universität München (TUM) have won the “International Space Station (ISS) Research Competition” in the US with their project Egypt Against Hepatitis C Virus (EGAHEP). As their prize,...

Prof. Ulrike Protzer und Dr. Felix Bohne überprüfen die Blutproben-Ergebnisse von HCV-infizierten Leberempfängern. (Bild: E. Mitterwallner / TUM)

Virus infection supports organ acceptance

Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not...

Prof. Ulrike Protzer (im Bild) und Prof. Mathias Heikenwälder konnten die virale DNA in Leberzellen zerstören. (Foto: TUM)

Attack on hepatitis B virus DNA

Scientists from the Technische Universität München and the Helmholtz Zentrum München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing...